ID29876A - Komposisi yang mengandung asam difosfonat - Google Patents

Komposisi yang mengandung asam difosfonat

Info

Publication number
ID29876A
ID29876A IDW20010789A ID20010789A ID29876A ID 29876 A ID29876 A ID 29876A ID W20010789 A IDW20010789 A ID W20010789A ID 20010789 A ID20010789 A ID 20010789A ID 29876 A ID29876 A ID 29876A
Authority
ID
Indonesia
Prior art keywords
diphosphonate
acids
contain
composition
diphosphonate acids
Prior art date
Application number
IDW20010789A
Other languages
English (en)
Indonesian (id)
Inventor
Rolf-Dieter Gabel
Walter Preis
Heinrich Woog
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8232769&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ID29876(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ID29876A publication Critical patent/ID29876A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IDW20010789A 1998-10-09 1999-10-01 Komposisi yang mengandung asam difosfonat ID29876A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98119102A EP0998932A1 (de) 1998-10-09 1998-10-09 Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung

Publications (1)

Publication Number Publication Date
ID29876A true ID29876A (id) 2001-10-18

Family

ID=8232769

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20010789A ID29876A (id) 1998-10-09 1999-10-01 Komposisi yang mengandung asam difosfonat

Country Status (35)

Country Link
US (2) US6294196B1 (pl)
EP (2) EP0998932A1 (pl)
JP (2) JP4471498B2 (pl)
KR (1) KR100522505B1 (pl)
CN (1) CN1150000C (pl)
AR (3) AR014081A1 (pl)
AT (1) ATE311887T1 (pl)
AU (1) AU752532B2 (pl)
BR (1) BR9914367A (pl)
CA (1) CA2346662C (pl)
CO (1) CO5050325A1 (pl)
CY (1) CY1105437T1 (pl)
CZ (1) CZ299008B6 (pl)
DE (1) DE69928819T2 (pl)
DK (1) DK1117412T3 (pl)
ES (1) ES2253919T3 (pl)
HK (1) HK1040914B (pl)
HR (1) HRP20010243B1 (pl)
HU (1) HU226457B1 (pl)
ID (1) ID29876A (pl)
IL (3) IL141912A0 (pl)
MA (1) MA27123A1 (pl)
ME (1) ME00637B (pl)
MY (1) MY126625A (pl)
NO (1) NO327447B1 (pl)
NZ (1) NZ510433A (pl)
PE (1) PE20001082A1 (pl)
PL (1) PL194552B1 (pl)
RS (1) RS49809B (pl)
RU (1) RU2207860C2 (pl)
SI (1) SI1117412T1 (pl)
TR (1) TR200100889T2 (pl)
TW (1) TW576742B (pl)
WO (1) WO2000021540A1 (pl)
ZA (1) ZA200102276B (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008645B2 (en) 1998-07-14 2006-03-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of inhibiting restenosis using bisphosphonates
US6984400B2 (en) 1998-07-14 2006-01-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of treating restenosis using bisphosphonate nanoparticles
IL125336A0 (en) 1998-07-14 1999-03-12 Yissum Res Dev Co Compositions for inhibition and treatment of restinosis
EP0998932A1 (de) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
NZ532994A (en) * 2001-12-21 2008-05-30 Procter & Gamble Method for the treatment of bone disorders using a bisphosphonate regimen, risedronate in particular
HUP0600680A3 (en) * 2001-12-24 2008-04-28 Teva Pharma Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it
US20040052843A1 (en) * 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
KR20140021045A (ko) * 2002-05-10 2014-02-19 에프. 호프만-라 로슈 아게 골다공증 치료 및 예방용 비스포스폰산
ES2530791T3 (es) † 2002-12-20 2015-03-05 Hoffmann La Roche Formulación de ibandronato de altas dosis
AU2006222690B2 (en) * 2002-12-20 2009-04-23 F. Hoffmann-La Roche Ag High dose ibandronate formulation
US10517883B2 (en) 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
WO2005072746A1 (ja) * 2004-01-30 2005-08-11 Astellas Pharma Inc. P2x受容体阻害剤
KR20070043043A (ko) * 2004-08-23 2007-04-24 테바 파마슈티컬 인더스트리즈 리미티드 고체 및 결정 이반드로네이트 나트륨 및 이들의 제조 방법
WO2008128056A1 (en) * 2004-10-08 2008-10-23 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including fpps, ggpps, and dpps
WO2006039721A2 (en) * 2004-10-08 2006-04-13 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
EP1848727B1 (en) * 2005-02-01 2015-06-17 F.Hoffmann-La Roche Ag Ibandronate polymorph b
CN101111504B (zh) * 2005-02-01 2011-12-21 霍夫曼-拉罗奇有限公司 伊班膦酸盐多晶型物a
US20070049557A1 (en) * 2005-08-24 2007-03-01 Hashim Ahmed Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
US20070191315A1 (en) * 2006-02-16 2007-08-16 Bengt Bergstrom Method for administering ibandronate
EP2001486A4 (en) * 2006-03-17 2010-12-29 Univ Illinois BIPHOSPHONATE COMPOUNDS AND CORRESPONDING METHODS
GB0616794D0 (en) 2006-08-24 2006-10-04 Arrow Int Ltd Solid dosage form
US20080139514A1 (en) * 2006-11-29 2008-06-12 Subhash Pandurang Gore Diphosphonic acid pharmaceutical compositions
CA2570949A1 (en) * 2006-12-12 2008-06-12 Apotex Pharmachem Inc. Ibandronate sodium propylene glycol solvate and processes for the preparation thereof
CA2671728C (en) * 2006-12-20 2015-05-26 Genpharm Ulc Pharmaceutical composition comprising a hot-melt granulated lubricant
EP2298286B8 (en) * 2009-09-18 2017-08-09 SiTec PharmaBio SL Process for dewatering of product powders
KR101244414B1 (ko) * 2010-11-05 2013-03-18 주식회사 바이오파마티스 고함량 이반드론산 함유 골다공증 예방 또는 치료용 조성물 및 이의 제조방법
EP2661262B1 (en) 2011-01-06 2017-11-15 Mahmut Bilgic Improved bisphosphonate formulations
JP5874545B2 (ja) * 2011-06-20 2016-03-02 アステラス製薬株式会社 経口投与用医薬組成物
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4639338A (en) 1984-08-06 1987-01-27 Ciba-Geigy Corporation Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
DE3434667A1 (de) 1984-09-21 1986-04-03 Henkel KGaA, 4000 Düsseldorf 4-dimethylamino-1-hydroxybutan-1,1-diphosphonsaeure, deren wasserloesliche salze, verfahren zu ihrer herstellung sowie ihre verwendung
US4798725A (en) 1986-06-16 1989-01-17 Norwich Eaton Pharmaceuticals, Inc. Sustained release capsule
DE3623397A1 (de) 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
ATE72816T1 (de) 1986-11-21 1992-03-15 Ciba Geigy Ag Neue substituierte alkandiphosphonsaeuren.
ATE60711T1 (de) * 1986-12-20 1991-02-15 Boehringer Mannheim Gmbh Clodronat-haltige arzneimittel und verfahren zur herstellung derselben.
FR2629716B1 (fr) 1988-04-07 1991-07-19 Sanofi Sa Composition pharmaceutique pour administration orale a base d'un derive d'acide diphosphonique
DE69231313T2 (de) 1991-11-22 2001-03-15 Procter & Gamble Pharmaceuticals, Inc. Risedronat enthaltende Arzneimittel mit verzögerter Wirkstoffabgabe
EP0583470A4 (en) 1992-01-10 1995-07-26 Obschestvo S Ogranichennoy Otv PHARMACEUTICAL COMPOSITION IN GRANULATE FORM AND PRODUCTION METHOD.
SE501389C2 (sv) 1992-04-24 1995-01-30 Leiras Oy Farmaceutiskt preparat och förfarande för dess framställning
DE4228552A1 (de) 1992-08-27 1994-03-03 Boehringer Mannheim Gmbh Diphosphonsäuren und deren Salze enthaltende Arzneimittel
US5358941A (en) 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
HU220872B1 (en) 1993-05-15 2002-06-29 Roche Diagnostics Gmbh Tablets containing dichloromethylene diphosphonic acid as active agent with enhanced bioavailability and process for producing them
TW390813B (en) 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
US5656288A (en) * 1995-06-08 1997-08-12 Sanofi Winthrop, Inc. Stable pharmaceutical compositions containing tiludronate hydrates and process for producing the pharmaceutical compositions
IL120265A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis - polyphosphonates or progestins and estrogen agonists
DE19615812A1 (de) 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
EP0998933A1 (de) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Verfahren zur Herstellung von bisphosphonathaltigen pharmazeutischen Zusammensetzungen zur oralen Applikation
EP0998932A1 (de) * 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung

Also Published As

Publication number Publication date
AR014081A1 (es) 2001-01-31
US20020006441A1 (en) 2002-01-17
AU752532B2 (en) 2002-09-19
NO327447B1 (no) 2009-06-29
ZA200102276B (en) 2002-06-19
KR20010073203A (ko) 2001-07-31
CN1150000C (zh) 2004-05-19
SI1117412T1 (sl) 2006-04-30
IL177940A0 (en) 2006-12-31
PL194552B1 (pl) 2007-06-29
AR047815A2 (es) 2006-02-22
JP2010116408A (ja) 2010-05-27
CN1319015A (zh) 2001-10-24
RS49809B (sr) 2008-08-07
IL177940A (en) 2012-05-31
JP2002527398A (ja) 2002-08-27
AU6467599A (en) 2000-05-01
MY126625A (en) 2006-10-31
HUP0103931A3 (en) 2003-01-28
HRP20010243A2 (en) 2002-04-30
WO2000021540A1 (en) 2000-04-20
AR069942A2 (es) 2010-03-03
ATE311887T1 (de) 2005-12-15
CZ20011233A3 (cs) 2001-09-12
NO20011714D0 (no) 2001-04-05
CA2346662A1 (en) 2000-04-20
TR200100889T2 (tr) 2001-07-23
NZ510433A (en) 2003-08-29
EP0998932A1 (de) 2000-05-10
NO20011714L (no) 2001-04-05
PL347243A1 (en) 2002-03-25
TW576742B (en) 2004-02-21
ES2253919T3 (es) 2006-06-01
DE69928819T2 (de) 2006-07-20
HUP0103931A2 (en) 2002-06-29
CY1105437T1 (el) 2010-04-28
KR100522505B1 (ko) 2005-10-18
CZ299008B6 (cs) 2008-04-02
IL141912A (en) 2006-12-10
US6294196B1 (en) 2001-09-25
ME00637B (me) 2008-08-07
RU2207860C2 (ru) 2003-07-10
DK1117412T3 (da) 2006-04-03
JP4471498B2 (ja) 2010-06-02
HK1040914B (zh) 2004-12-10
PE20001082A1 (es) 2000-10-18
IL141912A0 (en) 2002-03-10
YU20501A (sh) 2003-02-28
BR9914367A (pt) 2001-06-26
MA27123A1 (fr) 2005-01-03
DE69928819D1 (de) 2006-01-12
HRP20010243B1 (hr) 2011-02-28
US6627221B2 (en) 2003-09-30
HU226457B1 (en) 2008-12-29
HK1040914A1 (en) 2002-06-28
CA2346662C (en) 2006-05-09
CO5050325A1 (es) 2001-06-27
EP1117412B1 (en) 2005-12-07
EP1117412A1 (en) 2001-07-25

Similar Documents

Publication Publication Date Title
ID29876A (id) Komposisi yang mengandung asam difosfonat
DE69905371D1 (de) Härtbare zusammensetzung
ID22095A (id) Asam aril-akrilat ester
DE69824961D1 (de) Härtbare zusammensetzung
ID26222A (id) Hidroksamida asam(4-arilsulfonilamino)-tetrahidropiran-4-karboksilat
ID28833A (id) Turunan asam 3-aril-2-hidroksipropionat
ID28694A (id) Komposisi sampo
ID18145A (id) Asam fosfinik amida sebagai inhibitor metaloprotease matriks
DE69925322D1 (de) Polymerisierbare Zusammensetzung
ID26926A (id) Komposisi shampo pembentuk mode
ATE351896T1 (de) Brennstoffzusammensetzung
ID29430A (id) Komposisi herbisida
ID28329A (id) Komposisi-komposisi yang sesuai untuk sel-sel elektrokimia
ID20807A (id) Asam sulfonilaminokarboksilat
ID20809A (id) Asam diaminokarboksilat tersubstitusi
DE69908507D1 (de) Zusammensetzung zur Bekämpfung von schädlichen Arthropoden
DE69928862D1 (de) Zusammensetzung
DE69942892D1 (de) Gaserzeugende zusammensetzung
DE69832067D1 (de) Farbzusammensetzung
DE69821948D1 (de) Härtbare zusammensetzung
ID23250A (id) Komposisi paroksetin
ID21906A (id) Komposisi adesif
ID28810A (id) Senyawa-senyawa amida-omega asam n-arilsulfonilamino
ID17875A (id) Komposisi farmasi yang mengandung asam 4-oksobutanoat
DE69918180D1 (de) Kathodische elektrotauchlackzusammensetzung